Evidence map›Paper›PMID 20393732›Full record

ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2010

[Pterygium. Etiology, clinical aspects and novel adjuvant therapies].

L M Heindl, C Cursiefen

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. [Double vision in a 60-year-old male patient].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022
    Article
  4. [Pterygium and pinguecula].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Article
  5. [Pterygium: what about point of care biomarkers?]Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Article
  6. [Pterygium: pathogenesis, diagnosis and treatment].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Article
  7. Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2014
    Article
  8. Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study.Journal of ocular biology, diseases, and informatics · 2012
    Article
  9. [Operative techniques for surgical treatment of primary and recurrent pterygia].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

L M HeindlAugenklinik mit Poliklinik, Universität Erlangen-Nürnberg, Erlangen.
C Cursiefen
Friedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pterygium is a common UV-induced degeneration of the limbal conjunctiva. Indications for surgery include loss of visual acuity, increasing astigmatism, impending invasion of the optical axis and ocular surface discomfort. Measures to reduce the risk of recurrence include 1. an optimal surgical strategy (intra-operative use of antimetabolites and free conjunctival graft), 2. postoperative topical therapy with steroids and lubricants free of preservatives and 3. long-term UV protection. Novel anti-angiogenic treatment approaches for prevention of recurrence of pterygium are discussed.

Indexed as

Adrenal Cortex HormonesAlkylating AgentsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabCombined Modality TherapyConjunctivaDiagnosis, DifferentialEyeEye Protective DevicesHumansMitomycinPterygiumRadiation InjuriesSecondary PreventionAdrenal Cortex HormonesAlkylating AgentsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabMitomycin

Identifiers

PMID20393732
OpenAlexW72176406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.